Related Experiment Video

Updated: Jul 9, 2025

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
12:22

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

33.6K

Antigenic targets in clear cell renal cell carcinoma

Nicholas R Schindler1,2, David A Braun1,2

  • 1Section of Medical Oncology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.

Kidney Cancer (Clifton, Va.)
|November 28, 2023
PubMed

Insights

Identifying target antigens is crucial for improving immune checkpoint inhibitor (ICI) therapies in advanced renal cell carcinoma (RCC). This research explores potential antigens to enhance treatment efficacy and safety for RCC patients.

Area of Science:

  • Oncology
  • Immunology
  • Genetics

Background:

  • Immune checkpoint inhibitors (ICIs) have advanced advanced renal cell carcinoma (RCC) treatment.
  • However, many patients do not achieve long-term benefits, and some experience adverse effects.
  • RCC's modest mutation burden and lack of correlation between neoantigen load and ICI response necessitate further investigation.

Purpose of the Study:

  • To identify target antigens for effective anti-tumor immunity in RCC.
  • To improve the efficacy and safety of immunotherapies for RCC.
  • To explore antigen-directed therapies for clear cell RCC.

Main Methods:

  • Review of potential target antigen classes in RCC.
  • Analysis of previous and ongoing antigen investigation efforts.
  • Focus on clear cell histology.

Main Results:

  • Most patients with advanced RCC do not benefit from current ICIs.
  • Antigen identification is critical for understanding ICI response and resistance.
  • Targeting specific antigens may improve immunotherapy outcomes.

Conclusions:

  • Concerted antigen discovery efforts are needed for RCC.
  • Understanding target antigens will improve response and resistance knowledge.
  • This work lays the foundation for precision antigen-directed immunotherapies in RCC.
Keywords:
Renal cell carcinomaT cell receptorcancer vaccinechimeric antigen receptor T cellneoantigentumor antigen

More Related Videos

Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane05:36

Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane

Published on: February 8, 2020

9.0K
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

13.6K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
529